Sangamo Biosciences (SGMO) Tops Q4 EPS by 1c

Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $9.86 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Vireo Growth completes acquisition of C21 Investments